150 related articles for article (PubMed ID: 38224917)
21. Circulating and Imaging Biomarkers of Radium-223 Response in Metastatic Castration-Resistant Prostate Cancer.
Saylor PJ; Otani K; Balza R; Ukleja J; Pleskow H; Fisher R; Kusaka E; Otani YS; Badusi PO; Smith MR; Meneely E; Olivier K; Lowe AC; Toner M; Maheswaran S; Haber DA; Yeap BY; Lee RJ; Miyamoto DT
JCO Precis Oncol; 2024 Feb; 8():e2300230. PubMed ID: 38354328
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects.
Isaacsson Velho P; Qazi F; Hassan S; Carducci MA; Denmeade SR; Markowski MC; Thorek DL; DeWeese TL; Song DY; Tran PT; Eisenberger MA; Antonarakis ES
Eur Urol; 2019 Aug; 76(2):170-176. PubMed ID: 30293905
[TBL] [Abstract][Full Text] [Related]
23. Optimal usage of radium-223 in metastatic castration-resistant prostate cancer.
Cha TL; Wu TT; Vogelzang NJ; Huang CY; Huang SP; Lin CC; Ou YC; Pang ST; Shen DH; Wu WJ; Chang WY
J Formos Med Assoc; 2017 Nov; 116(11):825-836. PubMed ID: 29046247
[TBL] [Abstract][Full Text] [Related]
24. Circulating Tumor Cells as a Biomarker of Survival and Response to Radium-223 Therapy: Experience in a Cohort of Patients With Metastatic Castration-Resistant Prostate Cancer.
Carles J; Castellano D; Méndez-Vidal MJ; Mellado B; Saez MI; González Del Alba A; Perez-Gracia JL; Jimenez J; Suárez C; Sepúlveda JM; Manneh R; Porras I; López C; Morales-Barrera R; Arranz JÁ
Clin Genitourin Cancer; 2018 Dec; 16(6):e1133-e1139. PubMed ID: 30104161
[TBL] [Abstract][Full Text] [Related]
25. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
26. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
[TBL] [Abstract][Full Text] [Related]
27. Efficacy, patient-reported outcomes (PROs), and tolerability of the changing therapeutic landscape in patients with metastatic prostate cancer (MPC): a systematic literature review.
Seal BS; Asche CV; Puto K; Allen PD
Value Health; 2013; 16(5):872-90. PubMed ID: 23947983
[TBL] [Abstract][Full Text] [Related]
28. Pain response in a population-based study of radium-223 (Ra223) for metastatic castration-resistant prostate cancer.
Parimi S; Bondy S; Tsang E; McKenzie MR; Bachand F; Aparicio M; Duncan G; Sunderland K; Olson RA; Pai HH; Alexander AS; LaPointe V; Chi KN; Tyldesley S
Can Urol Assoc J; 2019 Oct; 13(10):E311-E316. PubMed ID: 31364977
[TBL] [Abstract][Full Text] [Related]
29. Icaritin-induced immunomodulatory efficacy in advanced hepatitis B virus-related hepatocellular carcinoma: Immunodynamic biomarkers and overall survival.
Qin SK; Li Q; Ming Xu J; Liang J; Cheng Y; Fan Y; Jiang J; Ye H; Tao H; Li L; Zheng L; Wei Z; Li S; Meng K; Ye B; Sun Y
Cancer Sci; 2020 Nov; 111(11):4218-4231. PubMed ID: 32889778
[TBL] [Abstract][Full Text] [Related]
30. Bone scan index can be a useful biomarker of survival outcomes in patients with metastatic castration-resistant prostate cancer treated with radium-223.
Naito M; Ukai R; Hashimoto K
Cancer Rep (Hoboken); 2019 Oct; 2(5):e1203. PubMed ID: 32721117
[TBL] [Abstract][Full Text] [Related]
31. Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223.
van der Doelen MJ; Stockhaus A; Ma Y; Mehra N; Yachnin J; Gerritsen WR; Nilsson S; van Oort IM; Ullén A
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3325-3334. PubMed ID: 33686456
[TBL] [Abstract][Full Text] [Related]
32. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
33. Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients.
Starzer AM; Berghoff AS; Hamacher R; Tomasich E; Feldmann K; Hatziioannou T; Traint S; Lamm W; Noebauer-Huhmann IM; Furtner J; Müllauer L; Amann G; Bauer S; Schildhaus HU; Preusser M; Heller G; Brodowicz T
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33762319
[TBL] [Abstract][Full Text] [Related]
34. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV
Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ
J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840
[TBL] [Abstract][Full Text] [Related]
35. Factors Associated With Survival Following Radium-223 Treatment for Metastatic Castration-resistant Prostate Cancer.
Wong WW; Anderson EM; Mohammadi H; Daniels TB; Schild SE; Keole SR; Choo CR; Tzou KS; Bryce AH; Ho TH; Quevedo FJ; Vora SA
Clin Genitourin Cancer; 2017 Dec; 15(6):e969-e975. PubMed ID: 28545997
[TBL] [Abstract][Full Text] [Related]
36. CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas.
Flores-Toro JA; Luo D; Gopinath A; Sarkisian MR; Campbell JJ; Charo IF; Singh R; Schall TJ; Datta M; Jain RK; Mitchell DA; Harrison JK
Proc Natl Acad Sci U S A; 2020 Jan; 117(2):1129-1138. PubMed ID: 31879345
[TBL] [Abstract][Full Text] [Related]
37. Immunophenotyping Reveals Longitudinal Changes in Circulating Immune Cells During Radium-223 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
Creemers JHA; van der Doelen MJ; van Wilpe S; Hermsen R; Duiveman-de Boer T; Somford DM; Janssen MJR; Sedelaar JPM; Mehra N; Textor J; Westdorp H
Front Oncol; 2021; 11():667658. PubMed ID: 34084750
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of STAT3 Promotes Effector T Cell Infiltration But also Immunosuppression in the HCC Tumor Microenvironment.
Sasaki T; Shigeta K; Kitahara S; Suzuki Y; Matsui S; Seishima R; Okabayashi K; Duda DG; Kitagawa Y
Anticancer Res; 2022 Nov; 42(11):5205-5215. PubMed ID: 36288859
[TBL] [Abstract][Full Text] [Related]
39. Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade.
Li Q; Wang Y; Jia W; Deng H; Li G; Deng W; Chen J; Kim BYS; Jiang W; Liu Q; Liu J
Clin Cancer Res; 2020 Apr; 26(7):1712-1724. PubMed ID: 31848190
[TBL] [Abstract][Full Text] [Related]
40. Differences in Tumor Microenvironment Dictate T Helper Lineage Polarization and Response to Immune Checkpoint Therapy.
Jiao S; Subudhi SK; Aparicio A; Ge Z; Guan B; Miura Y; Sharma P
Cell; 2019 Nov; 179(5):1177-1190.e13. PubMed ID: 31730856
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
